Dimensional Fund Advisors LP Has $28.75 Million Position in Avanos Medical, Inc. $AVNS

Dimensional Fund Advisors LP lessened its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 4.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 2,052,356 shares of the company’s stock after selling 105,175 shares during the period. Dimensional Fund Advisors LP’s holdings in Avanos Medical were worth $28,753,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Fifth Third Bancorp lifted its stake in Avanos Medical by 5,180.2% in the first quarter. Fifth Third Bancorp now owns 11,722 shares of the company’s stock valued at $164,000 after buying an additional 11,500 shares during the period. Louisiana State Employees Retirement System acquired a new position in Avanos Medical during the first quarter valued at approximately $289,000. Corient Private Wealth LLC bought a new stake in Avanos Medical in the fourth quarter valued at approximately $234,000. Alpine Global Management LLC acquired a new stake in Avanos Medical in the fourth quarter worth $177,000. Finally, Vident Advisory LLC acquired a new stake in Avanos Medical in the fourth quarter worth $585,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AVNS has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, July 20th. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. Finally, Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Avanos Medical presently has an average rating of “Reduce”.

Avanos Medical Price Performance

Avanos Medical stock opened at $24.99 on Thursday. The company has a 50 day moving average of $24.95 and a 200-day moving average of $20.04. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. Avanos Medical, Inc. has a twelve month low of $9.30 and a twelve month high of $25.49. The stock has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. The business had revenue of $182.20 million for the quarter, compared to analyst estimates of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the business posted $0.26 earnings per share. On average, equities research analysts anticipate that Avanos Medical, Inc. will post 1.06 EPS for the current fiscal year.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.